Table 4.

Reasons for non-initiation of adjuvant chemotherapy and for discontinuation of initiated adjuvant chemotherapy after oncologic resection for pancreatic ductal adenocarcinoma before (period 1) and after (period 2) S3 guideline implementation.

	Period 1 (09/’03–07/’07)	Period 2 (08/’07–08/’14)	p
Reasons for non-initiation	(n = 15)	(n = 16)
Not recommended a	n = 7 (47%)	n = 1 ( 6%)	0.0155
Patient refused	n = 5 (33%)	n = 5 (31%)	1.0000
Surgical complications	n = 3 (20%)	n = 3 (19%)	1.0000
Non-surgical complications b	n = 0	n = 2 (13%)	0.4839
Low performance status	n = 0	n = 2 (13%)	0.4839
Missing information	n = 1 ( 7%)	n = 3 (19%)	0.5996
Death	n = 1 ( 7%)	n = 0	0.4839
Reasons for discontinuation	(n = 12)	(n = 29)
Toxicity	n = 3 (25%)	n = 12 (41%)	0.4799
Tumor recurrence	n = 2 (17%)	n = 9 (31%)	0.4566
Patients decision	n = 0	n = 2 ( 7%)	1.0000
Death	n = 2 (17%)	n = 1 ( 3%)	0.2002
Concomitant diseases c	n = 2 (17%)	n = 5 (17%)	1.0000
Missing information	n = 3 (25%)	n = 0	0.0206

^aIn two patients of period 1 the original recommendation against adjuvant chemotherapy was skipped: one patient received adjuvant chemotherapy and one patient additive chemoradiation.

^bCerebral insult, pulmonary embolism, myocardial infarction.

^cInfections, thrombosis, pulmonary embolism, necessity for other operative interventions.